Anbio Biotechnology Limited (NNNN)
Summary
Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched Valuation
Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers.
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch
Anbio Biotechnology plans to raise $8.8 million in an IPO to commercialize its in vitro diagnostics products amid market risks. The company has experienced fluctuating revenue and profitability, with significant customer concentration risks. The global IVD market is projected to grow to $119 billion by 2030, but Anbio faces stiff competition from well-established industry players.
Anbio Biotechnology Limited Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YA Yinka Akinsola Blue Trust Inc. | 5 | $128.45 | $45.87 | -$82.58 | -64.29% |
 Curtis Burkholder Bare Financial Services, Inc | 15 | $385 | $165.15 | -$219.85 | -57.1% |
Anbio Biotechnology Limited (NNNN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Anbio Biotechnology Limited ever had a stock split?
Anbio Biotechnology Limited Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Michael Lau CEO | NASDAQ (NMS) Exchange | G0367B105 CUSIP |
| DE Country | 27 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Anbio Biotechnology specializes in the provision of in vitro diagnostics (IVD) products across diverse markets including the European Union, Asia Pacific, North America, South America, Africa, and beyond. The company is known for its innovative testing solutions, particularly in the realm of infectious diseases. Founded in 2021, Anbio is headquartered in Frankfurt am Main, Germany, focusing on enhancing the accessibility and effectiveness of diagnostic testing globally.
Products and Services
- SARS-CoV-2 Antigen Rapid Test
This test is designed for the quick detection of the SARS-CoV-2 virus, providing results in a matter of minutes. It plays a vital role in the rapid screening process, especially in areas requiring immediate results for public health management.
- SARS-CoV-2/Influenza A/B Antigen Rapid Test
This dual-function test effectively identifies both SARS-CoV-2 and influenza viruses, facilitating efficient respiratory illness diagnosis during peak flu seasons and potential COVID-19 outbreaks.
- Lateral Flow Immunoassay
An innovative testing method that allows for simple, rapid analysis of samples. This approach is often used for various diagnostics due to its ease of use and quick results, making it suitable for both at-home testing and point-of-care scenarios.
- Fluorescence Immunoassay
This highly sensitive assay utilizes fluorescent labels to enhance detection capabilities. It is commonly employed in laboratory settings for precise quantitative analysis of biological samples.
- Loop-Mediated Isothermal Amplification (LAMP)
LAMP is a nucleic acid amplification technique that enables rapid DNA or RNA amplification under isothermal conditions. This method is particularly advantageous for detecting pathogens quickly and efficiently, without the need for complex equipment.
- Chemiluminescence Immunoassay
This advanced immunoassay method relies on the emission of light during chemical reactions to achieve highly sensitive and specific detection of biomolecules, making it ideal for clinical laboratory diagnostics.
- Reverse-Transcription Polymerase Chain Reaction (RT-PCR)
RT-PCR is a critical technique for detecting and quantifying RNA viruses, including SARS-CoV-2. This method amplifies RNA sequences, allowing for the diagnosis of infections at very low levels of viral RNA.
